Sartorius SRT3.DE
What does Sartorius do?
Sartorius is a provider of products and services for biopharmaceutical manufacturing and laboratory research, headquartered in Göttingen. The company supplies consumables, equipment and software used in the development and production of biopharmaceuticals, such as bioreactors, filters, cell culture media, single-use bag systems and process monitoring solutions.
The business is divided into two segments: Bioprocess Solutions and Lab Products & Services. Customers are mainly pharmaceutical and biotechnology companies, contract development and manufacturing organizations, and academic research institutions. A large portion of revenue comes from recurring consumables needed in ongoing production processes. In terms of competition, Sartorius is among the leading providers of single-use technologies and filtration in bioprocessing and competes with large life science groups such as Thermo Fisher, Danaher and Merck KGaA, among others. Validated processes are usually closely tied to individual products, which binds customers over the long term.
Score profile
Rank vs. Medical Instruments & Supplies (28 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.
Metrics compared with the industry
On profitability and quality, Sartorius ranks in the middle in the group Medical Instruments & Supplies (4.9/10). On growth, the company ranks above average in the group Medical Instruments & Supplies (6.3/10). On valuation (higher = cheaper), the stock ranks below average in the group Medical Instruments & Supplies (3.3/10). On financial strength, Sartorius ranks in the bottom fifth in the group Medical Instruments & Supplies (1.7/10).
| Metric | Stock | Group median | Ranking |
|---|---|---|---|
| Forward P/E | 44.9x | 18.5x | better than 13 % |
| Trailing P/E | 94.3x | 34.2x | better than 7 % |
| PEG ratio | 0.9x | 1.3x | better than 69 % |
| EV/EBITDA | 25.5x | 15.7x | better than 24 % |
| Price/sales | 5.5x | 3.1x | better than 27 % |
| Price/book | 7.4x | 2.8x | better than 13 % |
| Revenue growth | 9.9% | 4.7% | better than 84 % |
| Earnings growth | 0.0% | 0.0% | better than 43 % |
| Gross margin | 45.4% | 54.7% | better than 30 % |
| Operating margin | 17.8% | 12.9% | better than 70 % |
| Net margin | 6.0% | 8.5% | better than 38 % |
| Return on equity | 7.9% | 6.3% | better than 59 % |
| Debt/equity | 94.4% | 36.0% | better than 13 % |
| Current ratio | 1.1x | 2.3x | better than 13 % |
| Free cash flow yield | 1.9% | 3.4% | better than 27 % |
| Dividend yield | 0.3% | 0.9% | – |
| Payout ratio | 23.4% | 38.9% | – |
| Beta | 1.51 | 0.85 | – |
Valuation: what is Sartorius worth?
Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give Sartorius a model range of 120.05 EUR to 151.51 EUR per share.
20 analysts, average rating “Buy”, average price target 297.50 EUR (+2.4%).
The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.
What the business depends on
- Demand depends on research and production activities in the biopharmaceutical industry, particularly in antibodies and new therapy types.
- Recurring consumables in approved manufacturing processes provide predictable follow-on revenue once customers have adopted a product in production.
- Pharma customers' willingness to invest and financing conditions for biotechnology affect sales of equipment and systems.
Risks
- Restrained investment or inventory reduction at customers can significantly weigh on revenue and capacity utilization in the short term.
- Strong competitors and possible pricing pressure from large customers can squeeze margins in the bioprocess business.
- Dependence on regulatory-approved processes, global supply chains and currency effects makes planning more difficult.
What to look for with Sartorius
The ratio of orders received to revenue (book-to-bill) shows early on whether customer demand and inventory levels will support or weigh on future revenue development.